EUVIMEDEUVIMED entdecken
Crossref

Discovery of Galactopyranose‐1‐carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin‐3 Inhibitors

Cornelia Zumbrunn iD, Luboš Remen, Christoph P Sager iD, Corinna Grisostomi, Christina Stamm, Daniela Krüsi, Sven Glutz, Gunther Schmidt, Oliver Nayler, Marc Iglarz, Aengus Mac Sweeney iD, Alain Chambovey und 9 weitere

ChemMedChem · 2025

DOI: 10.1002/cmdc.202401012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Cornelia Zumbrunn und 20 weiteren Autor:innen. Beteiligte Einrichtung: Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland. Hauptthemen laut MEDLINE: Galactose, Galectin 3, Drug Design, Small Molecule Libraries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galectin‐3 (Gal‐3), a β‐galactoside‐binding lectin, is implicated in diverse cellular functions ranging from immune response modulation to tissue homeostasis. Notably, increased Gal‐3 expression has been linked to the progression of numerous diseases, including cancer, fibrosis, and cardiovascular disorders, underscoring its potential as a therapeutic target. Small molecule inhibitors have been discovered and are valuable tools to study such diseases. We report here the discovery of novel, galactose‐based, small molecule inhibitors such as compound 12 which are orally bioavailable and show efficacy in a mouse model of acute liver injury and fibrosis (CCl 4 model). The use of structure‐based drug design (docking of a virtual library of amides based on acid 2 ) was key in the process towards potent, nanomolar inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GalactoseGalectin 3Drug DesignSmall Molecule LibrariesAmidesCarbon TetrachlorideDrug DiscoveryMice, Inbred C57BLAnimalsMiceChemical and Drug Induced Liver InjuryFibrosisCrystallography, X-RayMicrosomes, LiverHumansAdministration, OralDose-Response Relationship, DrugLiver CirrhosisMolecular Docking SimulationMolecular StructureStructure-Activity Relationship

Stichwörter der Autor:innen

Galectin-3cancerfibrosisinflammationinhibitor

Substanzen

GalactoseCarbon TetrachlorideGalectin 3Small Molecule LibrariesAmides

Autor:innen und Institutionen

  • Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland.

ORCID-Profile: Cornelia Zumbrunn, Christoph P Sager, Aengus Mac Sweeney, Solange Meyer, Magali Vercauteren, John Gatfield, Martin H Bolli

Zitieren

APA

Zumbrunn, C., Remen, L., Sager, C. P., Grisostomi, C., Stamm, C., Krüsi, D., Glutz, S., Schmidt, G., Nayler, O., Iglarz, M., Mac Sweeney, A., Chambovey, A., Müller, M., Mueller, C., Bourquin, G., Meyer, S., Hühn, E., Cattaneo, C., Vercauteren, M., …, & Bolli, M. H. (2025). Discovery of Galactopyranose‐1‐carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin‐3 Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.202401012

Vancouver

Zumbrunn C, Remen L, Sager CP, Grisostomi C, Stamm C, Krüsi D, et al. Discovery of Galactopyranose‐1‐carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin‐3 Inhibitors. ChemMedChem. 2025. doi:10.1002/cmdc.202401012

BibTeX
@article{Zumbrunn2025,
  author = {Zumbrunn, Cornelia and Remen, Luboš and Sager, Christoph P and Grisostomi, Corinna and Stamm, Christina and Krüsi, Daniela and Glutz, Sven and Schmidt, Gunther and Nayler, Oliver and Iglarz, Marc and Mac Sweeney, Aengus and Chambovey, Alain and Müller, Manon and Mueller, Celia and Bourquin, Geoffroy and Meyer, Solange and Hühn, Eva and Cattaneo, Christophe and Vercauteren, Magali and Gatfield, John and Bolli, Martin H},
  title = {Discovery of Galactopyranose‐1‐carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin‐3 Inhibitors},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202401012}
}
Kostenlos starten →